:782-95.
. However, in another report using the same model, TSA potentiated neointima formation (12) .
Opposite effects of TSA were also reported on proliferation/migration of primary rat SMCs (12) (13) (14) .
Moreover, whereas earlier reports indicated that HDACs 2, 4, and 5 repress SMC contractile gene expression (15) , a more recent study showed that TSA treatment diminished SMC contractile proteins in human primary cells (16) .
These disparities inspired us to explore differential functions of individual HDACs. We chose the unique HDAC6 from class IIb and HDAC3 from class I for contrast. Whereas HDAC3 is typically chromatinassociated, HDAC6 is essentially a cytosolic protein although its nuclear presence has also been reported (7) . Both are implicated in vascular diseases; however, the knowledge of their regulations of SMC marker (contractile) proteins is conspicuously lacking. Our data show that HDAC6 inhibition elevates, whereas HDAC3 inhibition reduces, SMC marker protein levels. With an initial objective to compare these 
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HDAC6 Regulates MRTF-A/SRF 783 a surprising finding that inhibition of HDAC6, known as a cytosolic enzyme, robustly increased the nuclear activity of serum response factor (SRF). This result could be rationalized by another novel finding reported here; that is, HDAC6 inhibition elevated acetylation and total protein of myocardin-related transcription factor A (MRTF-A), a master regulator that can activate SRF-directed contractile gene transcription if undergoing a cytosol-nucleus translocation. Our findings are unexpected also because there are few reports on HDAC6 modulation of transcription factor nuclear activities (6, 7) . In addition, our in vivo data show that a selective HDAC6 inhibitor (but not HDAC3 inhibitor) effectively reduced neointima in a rat vascular injury model. As such, the present study highlights the unique HDAC6 regulatory mechanism in SMC pathobiology that could be targeted in vivo for neointima mitigation. Proliferation was determined by using the CellTiterGlo Luminescent Cell Viability kit (Promega, Madison, Wisconsin) following manufacturer's instructions, as previously described (17 Jose, California) (250-ms integration).
To determine cell migration, scratch (wound healing) assay was performed as described in our previous report (17) . Briefly, SMCs were cultured to a 90% Tubastatin A also increased SMHC, albeit not to a MOVAS cells were starved with 0.5% fetal bovine serum for overnight, and then pretreated with 5 mmol/l tubastatin A or 5 mmol/l RGFP966 or vehicle control (equal amounts of dimethylsulfoxide) for 2 h before the addition of 20 ng/ml of platelet-derived growth factor-BB (PDGF-BB). Data are quantified as fold changes versus control (normalized value as 1, condition specified later); mean AE SEM; n ¼ 3 independent experiments; *p < 0.05 compared with control (one-sample Student's t-test). 
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tubastatin A pretreatment on the nuclear/cytosolic ratio of MRTF-A but observed no significant changes (data not shown). However, our data showed that tubastatin A increased MRTF-A total protein ( Figure 3A) . We then determined acetylation levels of MRTF-A, as acetylation generally contributes to protein stabilization (7). Considering that there are numerous acetylated proteins in the cell lysate milieu, we performed immunoprecipitation to specifically pull down MRTF-A. Interestingly, our data showed that pre-treatment with tubastatin A robustly increased MRTF-A acetylation ( Figure 3B ). This result raised the possibility that HDAC6 may serve as an enzyme that deacetylates MRTF-A. Indeed, Zhang et al. We found that 2 weeks after balloon angioplasty, treatment with tubastatin A decreased IH (measured as the intima/media area ratio) by 40% and increased lumen size by up to 60% compared with vehicle control ( Figures 4A and 4B ). There was no difference in the overall vessel size measured as EEL length.
These data indicate that perivascular application of tubastatin A effectively mitigated restenosis without causing constrictive remodeling (reduced EEL length). In contrast, RGFP966 slightly increased IH and decreased lumen size, although the changes were not statistically significant ( Figures 4C and 4D ). We also tried a different hydrogel (Pluronic gel) to deliver RGFP966, and Apicindin, another commonly used selective HDAC3 inhibitor, but neither experiment resulted in neointimal inhibition (data not shown). Therefore, the results indicate that HDAC6
inhibitor, but not HDAC3 inhibitor, effectively miti-
Finally, the effect of HDAC inhibition on a-SMA 
DISCUSSION
In the present study, we made an unanticipated finding that inhibition of HDAC6, which is best known as cytosolic localized, enhances SRF nuclear activity and preserves SMC contractile protein levels. Mechanistically, another novel finding was that HDAC6
inhibition increases acetylation and total protein levels of MRTF-A, a powerful co-factor that resides in the cytosol but is able to translocate to the nucleus to HDACs. In these studies, SMC proliferation and migration were determined, but SMC inflammation and dedifferentiation were generally left unexplored.
Given our finding that inhibiting HDAC6 (class IIb) up-regulates SMC markers, it is seemingly contradictory that TSA reduced these proteins in a previous study (16) . However, our data also showed that inhibiting HDAC3, a class I member, reduced a-SMA, consistent with the previous report. As the outcome of using a pan-HDAC inhibitor represents the sum of the effects mediated by all the targeted HDACs, the gross effect of a pan inhibitor may vary depending on multiple factors (e.g., concentration or treatment duration of the inhibitor). We hence speculate that in this previous study using TSA (16) , the effect of 
